Masitinib is an anticancer chemotherapeutic and anti-inflammatory compound used in veterinary medicine. Masitinib inhibits c-Kit and PDGFR, increasing survival time in the treatment of mast cell tumors and other cancers. In vitro, masitinib increases levels of caspases 3 and 7, inducing apoptosis. Masitinib also decreases airway inflammation and edema in feline allergic asthma models and also decreases the patient-rated severity of multiple sclerosis in clinical settings. Masitinib also exhibits potential efficacy against Alzheimer’s disease when given as an adjunct therapy, slowing cognitive decline.